Axsome Therapeutics (AXSM) Misses Q1 EPS by 43c

Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($1.26), $0.43 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $191.2 million versus the consensus estimate of $193.46 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Victrex Plc. (VCT:LN) (VTXPF) PT Raised to GBP8.30 at Deutsche Bank
• BTIG on Braze Inc (BRZE): 'AI story continues to get better heading into its Forge conference'